220
Participants
Start Date
October 31, 2012
Primary Completion Date
December 31, 2016
Study Completion Date
May 16, 2017
AT13387
HSP90 inhibitor
Crizotinib
ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene1, receptor tyrosine kinase) inhibitor
Columbia University Medical Center, New York
Montefiore Medical Center, The Bronx
Institut Paoli-Calmettes, Marseille
CHU de Caen-Hopital Cote de Nacre, Caen
Thomas Jefferson University, Philadelphia
Christiana Hospital, Newark
Virginia Cancer Specialists, Fairfax
Centre Hospitalier Regional Universitaire Besancon, Besançon
Cone Health Cancer Center, Greensboro
Duke University Medical Center, Durham
Centro Integral Oncologico Clara Campal, Madrid
Hospital Regional Universitario de Malaga, Málaga
Florida Hospital Cancer Institute, Orlando
Sarah Cannon Research Institute, Nashville
Centre Hospitalier de Grenoble, Grenoble
The West Clinic, Germantown
Ohio State University Medical Center, Columbus
Cleveland Clinic, Cleveland
Oncology Hematology in Cincinnati, Cincinnati
University of Cincinnati Cancer Institute, Cincinnati
Indiana University Melvin and and Bren Simon Cancer Center, Indianapolis
University of Michigan Medical Center, Ann Arbor
Barbara Ann Karmanos Cancer Institute, Detroit
University of Wisconsin-Carbone Cancer Center, Madison
Mayo Clinic-Rochester, Rochester
CHRU de Lille, Lille
Northwestern University The Feinberg School of Medicine, Chicago
University of Chicago, Chicago
Washington University School of Medicine, St Louis
University of Nebraska Medical Center Eppley Cancer Center, Omaha
Centre Hospitalier Lyon Sud, Pierre-Bénite
Hopital Tenon, Paris
University of Texas Southwestern Medical Center, Dallas
University of Colorado Denver, Aurora
Mayo Clinic-Scottsdale, Scottsdale
USC Norris Comprehensive Cancer Center, Los Angeles
UCLA Medical Center, Los Angeles
Innovative Clinical Research Institute, Whittier
Sharp Clinical Oncology Research-Sharp Memorial Hospital, San Diego
Hopital Saint Antoine, Créteil
Institut Gustave Roussy, Villejuif
Providence Portland Medical Center, Portland
Swedish Cancer Institute, Seattle
University of Washington Medical Center, Seattle
University of California, San Diego Medical Center, La Jolla
Yale University School of Medicine-Yale Cancer Center, New Haven
H. Lee Moffitt Cancer Center & Research Institute, Tampa
Dartmouth Hitchcock Medical Center, Lebanon
The Pennsylvania State University-Penn State, Hershey
Atlantic Clinical Cancer Research Unit, Halifax
McGill University Health Center, Montreal, Quebec
Institut Universitaire de Cardiologie et de Pneumologie De Quebec, Sainte-Foy, Quebec
Princess Margaret Hospital, Toronto, Ontario
Cancer Care Manitoba, Winnipeg
CHU Toulouse-Hopital Larrey, Toulouse
Chungbuk National University Hospital, Cheongju-si
The Catholic University of Korea, St. Vincent's Hospital, Gyeonggi-do
Chonnam National University Hwasun Hospital, Hwasun-gun Jeonnam
National Cancer Center, Korea
Seoul National University Bundang Hospital, Seongnam
Severance Hospital, Yonsei University Health System, Seoul
Samsung Medical Center, Seoul
Asan Medical Center, Seoul
Hospital Germans Trias i Pujol, Badalona
Hospital Universitari Quiron Dexeus Barcelona, Barcelona
Lead Sponsor
Astex Pharmaceuticals, Inc.
INDUSTRY